New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:10 EDTPTLAPortola announces andexanet alfa, enoxaparin 'positive' Phase 2 data
Portola Pharmaceuticals announced that a Phase 2 proof-of-concept study in healthy volunteers demonstrated that andexanet alfa immediately reversed the anticoagulation activity of enoxaparin. Andexanet alfa was well tolerated with no serious adverse events reported. Detailed data will be presented during both oral and poster sessions at the 60th Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis. Portola is developing andexanet alfa to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery. Andexanet alfa was well tolerated with no thrombotic events or serious adverse events reported. No antibodies to andexanet alfa, Factor Xa or Factor X were observed.
News For PTLA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
09:22 EDTPTLAOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTPTLAPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
November 12, 2014
08:02 EDTPTLACredit Suisse to hold a conference
Subscribe for More Information
November 10, 2014
16:14 EDTPTLAPortola says advancing oral, dual Syk-JAK kinase inhibitor to next stage
"The third quarter marked another successful period of execution for Portola as we achieved a number of milestones across our three wholly-owned clinical programs. We announced positive Phase 3 study results with our universal Factor Xa inhibitor antidote, andexanet alfa, in which all primary and secondary endpoints were achieved with high statistical significance. We increased enrollment and remain on track to complete the betrixaban pivotal Phase 3 APEX Study by the end of 2015. In addition, we have made the decision to advance our oral, dual Syk-JAK kinase inhibitor, cerdulatinib, to the next stage of development based on the tolerability and clinical activity seen thus far in the ongoing Phase 1 study in patients with hematologic cancers," said William Lis, chief executive officer of Portola.
16:13 EDTPTLAPortola Pharmaceuticals reports Q3 EPS (86c), consensus (92c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use